Bronchopulmonary Dysplasia
Pipeline by Development Stage
Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.
Key Trends
- Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
- Major patent expirations 2026-2031 creating $7.8B revenue cliff
- High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity
Career Verdict
Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 46% | Launch | Growing | 15.0yr |
| 2 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 19% | Peak | Stable | |
| 3 | TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol) | GSK | $4.5B | 11% | Peak | Declining | 4.9yr |
| 4 | CREON (pancrelipase) | AbbVie | $1.5B | 4% | Approaching LOE | Declining | |
| 5 | BREO ELLIPTA (fluticasone/vilanterol) | GSK | $1.4B | 4% | Peak | Declining | 4.9yr |
Drug Class Breakdown
dominant market driver
fragmented portfolio
rapidly expanding
legacy product
patent cliff approaching
mature maintenance therapy
Career Outlook
StableRespiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.
Breaking In
New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.
For Experienced Professionals
Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.
In-Demand Skills
Best For
Hiring Landscape
The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.
Top Hiring Companies
By Department
Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 25 trials with date data
Clinical Trials (25)
Total enrollment: 2,650 patients across 25 trials
Preterm Infant Inhaled Albuterol Dosing
OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP
Treatment of Classic Mid-trimester PPROM by Means of Continuous Amnioinfusion
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
High Frequency Ventilation in Premature Infants (HIFI)
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
Safety of Sildenafil in Premature Infants
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants
Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study
Inhaled Ciclesonide Study in Preterm Infants
A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)
A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD
Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants
Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia
Montelukast in Very Low Birthweight Infants
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study
Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
Related Jobs in Respiratory
Patient Education Consultant
Patient Education Consultant
(Bio-)Chemiker Analytik, M.Sc. (w/m/d)
Principal Process Engineer
Compliance Director
Medical Device Sales Associate Territory Account Manager
Phase Legend
Key Insights
Related Indications
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.